Which pharmacovigilance for vaccines?;Quelle pharmacovigilance pour les vaccins?

Therapie

Volumn 62, Issue 3, 2007, Pages 245-247

  Le Louët, Hervé ^a   Loupi, Elisabeth ^b,d   Haramburu, Françoise ^c   Abelin, Atika ^d   Guillemot, Didier ^e   Jacquet, Alexis ^f   Kreft Jais, Carmen ^f   Launay, Odile ^g   Malbezin, Muriel ^h  

^a HENRI MONDOR HOSPITAL   (France)

^b SANOFI PASTEUR   (France)

^c HÔPITAL PELLEGRIN   (France)

^d Sanofi Pasteur

^e Centre de Ressources   (France)

^f Afssaps ^*

^g Groupe Hospitalier Cochin Saint Vincent de Paul ^*  (France)

^h GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Epidemiology; Pharmacovigilance; Vaccines

Indexed keywords

ALUMINUM; ANTIINFECTIVE AGENT; HEPATITIS B VACCINE; MEASLES MUMPS RUBELLA VACCINE; VACCINE;

AUTISM; CLINICAL PHARMACOLOGY; COMMUNITY CARE; CONFERENCE PAPER; DRUG EFFICACY; DRUG MECHANISM; DRUG QUALITY; DRUG SURVEILLANCE PROGRAM; DRUG USE; FASCIITIS; FOLLOW UP; HEALTH EDUCATION; HEALTH SURVEY; IMMUNOGENICITY; INFECTION PREVENTION; INTERPERSONAL COMMUNICATION; MICROBIOLOGY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PUBLIC HEALTH; RISK MANAGEMENT; VACCINATION; VACCINE PRODUCTION; DRUG INDUSTRY; HUMAN; INFORMATION PROCESSING; MEDICAL EDUCATION; POSTMARKETING SURVEILLANCE; REVIEW; STANDARD;

DATA COLLECTION; DRUG INDUSTRY; EDUCATION, MEDICAL; HEALTH EDUCATION; HUMANS; POPULATION SURVEILLANCE; PRODUCT SURVEILLANCE, POSTMARKETING; RISK MANAGEMENT; VACCINES;

EID: 38449106598     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie:2007048     Document Type: Conference Paper

References (13)

1. Code de la santé publique. Art L-5111-1
2. Directive 65/65/CEE du Conseil, du 26 janvier 1965, concernant le rapprochement des dispositions législatives, réglementaires et administratives, relatives aux spécialités pharmaceutiques
3. USA/FDA. CFR (Code of Federal Regulation) Title 21: Food and drugs. Chapter 1: Food and Drug administration. Subchapter F: Biologics. Part 600: Biological products : General
4. Canada / PPHB. Guidelines for reporting adverse events associated with vaccine products. Canada Communicable Disease Report. Volume 26 - S1 - February 2000
5. Guideline on clinical evaluation of new vaccines. EMEA/CHMP/VWP/382702/ 2006, October 2006
6. Concept paper for a guideline on the conduct of pharmacovigilance for vaccines. PhVWP/372004/2005 - October 2005
7. www.ecdc.eu.int/Health_topics/VI/VI_newsletter.html
8. Anon. Calendrier vaccinal 2006 ; avis du Conseil Supérieur d'Hygiène publique de France. BEH No 2930/2006
9. Laribière A, Miremont-Salamé G, Reyre H, et al. Surveillance of adverse effects during a vaccination campaign against meningitis C. Eur J Clin Pharmacol. 2005; 61: 907-11
10. Bagheri H, Gony M, Montastruc JL. A propos d'une campagne de vaccination contre la méningite C dans les Hautes-Pyrénées : réflexions de pharmacovigilance. Therapie 2005; 60: 287-94
11. Anon. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease - United States, 1998-2003. PPR weekly 2005; 54: 893-7
12. Metlay JP, Fishman NO, Joffe M, et al. Impact of pediatric vaccination with pneumococcal conjugate vaccine on the risk of bacteremic pneumococcal pneumonia in adults. Vaccine 2006; 24: 468-75
13. Law DKS, Lorange M, Ringuette L, et al. Invasive meningococcal disease in Quebec, Canada, due to an emerging clone of ST-269 serogroup B meningococci with serotype antigen 17 and serosubtype antigen P1.19 (B:17:P1.P19). J Clin Microbiol 2006; 44: 2743-9